TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01422811

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent strategy to reduce avoidable length of stay
Description: The strategy comprises two integrated components:~1. Distribution of two monthly reports, one consisting in the list of patients who, through data collection performed, are classified to be present on the ward although their clinical status is considered compatible with discharge; the other featuring individual length of stay profiles for each physician operating in the intervention arm (information taken from administrative data), allowing comparisons with the rest of the medical staff;~2. Audits performed by professionals of each ward of the intervention arm designed to discuss cases judged to be compatible with discharge. The organization of this work are left to the wards, without any interference from the project team.

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: No interventions (reporting, auditing) are planned; nevertheless control ward physicians know study aims and are informed about their patient's data collection.
Study: NCT03957655

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHED group
Description: 1x10E6 MSCs/kg body weight will be administered via peripheral vein for 4 times at week 0,4,8,12
Study: NCT01076842

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin-Levemir
Description: Levemir once daily, force titrated to reach a fasting plasma glucose of 100 mg/dl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide-Bayetta
Description: Exenatide twice daily, started at a dose of 5 mcg b.i.d. and increased to 10 mcg b.i.d. after 2 weeks if the fasting plasma glucose of 100 mg/dl is not reached. Exenatide will be administered immediately before breakfast and dinner meals. No further increase in the dose of exenatide will take place. For those who are unable to tolerate exenatide at a 10 mcg b.i.d. dose, it will be reduced to 5 mcg b.i.d. and continued until week 12.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin-Levemir and Exenatide-Bayetta
Description: Patients from either Group A or Group B who have not reached the goal A1C of 6.5% will be assigned to this Group. They will receive the drug assigned to the other group in addition to the one they were originally assigned.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SenseWear Pro3® armband
Description: For one-week prior to beginning the assigned medication and for one week , week 11 and week 23, the patients will wear the SenseWear Pro3® armband for collection of ancillary physiologic data

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SenseWear Pro3® armband
Description: For one-week prior to beginning the assigned medication and for one week , week 11 and week 23, the patients will wear the SenseWear Pro3® armband for collection of ancillary physiologic data

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SenseWear Pro3® armband
Description: For one-week prior to beginning the assigned medication and for one week , week 11 and week 23, the patients will wear the SenseWear Pro3® armband for collection of ancillary physiologic data

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DexCom CGM
Description: For one-week prior to beginning the assigned medication and for one week , week 11 and week 23, the patients will wear the DexCom CGM for collection of continuous blood glucose concentrations.
Study: NCT02143284

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopy exploratory single arm (EndoChoice FUSE(TM) System)
Description: The investigational device will be applied in otherwise standard procedures (upper and lower Gastrointestinal tract endoscopy)
Study: NCT04120207

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based Pilates
Description: The Home-based Pilates group will complete two Pilates classes at home, twice weekly, for a period of eight weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Delayed-start Pilates
Description: The Delayed-start group will maintain their regular daily activities, and be provided with a copy of the Pilates DVD following the intervention, for their own use.
Study: NCT01076842

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DexCom CGM
Description: For one-week prior to beginning the assigned medication and for one week , week 11 and week 23, the patients will wear the DexCom CGM for collection of continuous blood glucose concentrations.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DexCom CGM
Description: For one-week prior to beginning the assigned medication and for one week , week 11 and week 23, the patients will wear the DexCom CGM for collection of continuous blood glucose concentrations.
Study: NCT00307515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrin Sealant 2 (FS2)
Description: FS2 Surgical Sealant Kit: Biological Active Component containing Human Fibrinogen 55-85 mg/mL and Thrombin containing Thrombin 800-1200 IU/mL and Calcium Chloride 5.6-6.2 mg/mL

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxidized Regenerated Cellulose (Surgicel)
Description: Commercially available Surgicel used within label.
Study: NCT05263102

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal Moisturizing Gel
Description: All eligible subjects will received the Vaginal Moisturizing Gel twice per week, total in 8 weeks
Study: NCT04013438

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Strogen
Description: The OCP-LD begins in 2 to 3 days of the last menstrual cycle and then 500 μgr/d GnRH-a will received on day 17 for fourteen days. Then in 2-3 days of the next menstrual cycle, GnRH-a reduced to 200 μgr/d dose. the patients will receive 6 mg oral that will be continued for 14 days and during this time endometrium thickness evaluated by vaginal ultrasonography. If endometrial thickness is estimated ≥7mm, intramuscularly progesterone 100 mg/d will be started. After the onset of progesterone (days 17 to 18 cycles) frozen embryos transferred. Control group receive 6 mg oral estrogen and 100 mg intramuscularly progesterone until 12 week of pregnancy. The levels of maternal estrogen and progesterone was measured at the time of the starting day of progesterone (day 15), the day of embryo transfer, 6 and 12 weeks of pregnancy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Strogen
Description: The OCP-LD begins in 2 to 3 days of the last menstrual cycle and then 500 μgr/d GnRH-a will received on day 17 for fourteen days. Then in 2-3 days of the next menstrual cycle, GnRH-a reduced to 200 μgr/d dose. the patients will receive 6 mg oral that will be continued for 14 days and during this time endometrium thickness evaluated by vaginal ultrasonography. If endometrial thickness is estimated ≥7mm, intramuscularly progesterone 100 mg/d will be started. After the onset of progesterone (days 17 to 18 cycles) frozen embryos transferred. In patients 35 days after embryo transfer and observation of gestational sac with heart beat (6 weeks of pregnancy) by ultrasound, exogenous estrogen will discontinued while progesterone will remain daily use until twelfth week of pregnancy. The levels of maternal estrogen and progesterone was measured at the time of the starting day of progesterone (day 15), the day of embryo transfer, 6 and 12 weeks of pregnancy.
Study: NCT01241669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5555
Description: Drug: Oral E5555 400 mg/matching placebo, oral metformin 500 mg, iohexal 20 mL intravenous (IV), and para-aminohippuric acid (PAH) 7 mg/kg IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5555
Description: Drug: Oral E5555 100 mg/matching placebo, oral metformin 500 mg, iohexal 20 mL intravenous (IV), and para-aminohippuric acid (PAH) 7 mg/kg IV bolus.
Study: NCT00850018

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Monthly blood transfusion regimen
Description: Participants will receive blood transfusions at 3- to 4-week intervals for 6 months for the treatment of SCD-related anemia; the total number of transfusions that participants will receive will vary between six and eight.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will receive usual care for the treatment of SCD.
Study: NCT02617732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tianqi capsule
Description: The patients with type 2 diabetes are divided into two groups, one is experimental group, and the other is placebo group.~The experimental group patients are treated with Tianqi capsule by oral, 5 pills three times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The patients with type 2 diabetes are divided into two groups, one is experimental group, the other is placebo group.~The placebo group patients are treated with placebo by oral, 5 pills three times a day
Study: NCT02304783

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piroxicam
Description: Patients allocated to this arm received, as a second line treatment of renal colics, a five days treatment with 20 mg piroxicam associated with placebo per day and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients allocated to this arm received a five days treatment with Placebo and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: Patients allocated to this arm received a five days treatment with Paracetamol and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.
Study: NCT03759457

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula (AIRVO2)
Description: High-flow nasal cannula (HFNC) delivers oxygen flows of up to 60 L/min. The gas source (air/oxygen blender, ventilator, or turbine flow-generator) is connected via an active heated humidifier to a nasal cannula and allows FiO2 adjustment independently from the flow
Study: NCT04281160

Intervention type: DEVICE
Intervention: BeCare Mobile App
Description: The BeCare App is a mobile application that will perform routine assessments of neurological function in individuals with MS and address the most relevant domains that are affected in MS: cognition, afferent visual functioning, motor functioning, fine motor functioning, coordination, gait, and endurance

Intervention type: DEVICE
Intervention: BeCare Mobile App
Description: The BeCare App is a mobile application that will perform routine assessments of neurological function in individuals with MS and address the most relevant domains that are affected in MS: cognition, afferent visual functioning, motor functioning, fine motor functioning, coordination, gait, and endurance
Study: NCT02096146

Intervention type: PROCEDURE
Group type: OTHER
Intervention: TMT Fusion plate
Description: Patients are treated with TMT Fusion Plate a post-market device to encourage bony fusion of the 1st TMT joint.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Two crossed screws
Description: Patients are treated with two crossed screws.This procedure is a standard treatment for 1st TMT joint fusion.
Study: NCT01223872

Intervention type: OTHER
Intervention: interview
Description: * Standard Interview (2-15 years from last treatment)~* Demographic data interview (pre-initial study interview)

Intervention type: OTHER
Intervention: clinic visit and interview
Description: * REACH Clinic Visit(initial or regular)~* Post-REACH Clinic Interview (3mos from initial or regular clinic visit)~* Demographic data interview(pre-initial study interview)

Intervention type: OTHER
Intervention: interviews and clinic visit
Description: * Pre-REACH Clinic Interview(2-15 yrs from last treatment)~* REACH Clinic Visit(initial or regular)~* Post-REACH Clinic Interview(1mo from initial clinic visit)~* Post-REACH Clinic Interview(3mos from initial or regular clinic visit)~* Demographic data interview(pre-initial study interview)
Study: NCT01457859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triclosan
Description: Triclosan coated surgical sewing threads (VICRYL+ and MONOCRYL+) applied for leg wound closure after CABG

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional non-coated surgical sutures
Description: Conventional non-coated surgical sewing threads (POLYSORB and BIOSYN) will be applied after CABG for leg wound closure
Study: NCT01435031

Intervention type: DEVICE
Group type: OTHER
Intervention: CTO Treatment Device
Description: Subjects receiving at least 1 of the following for the treatment of CTO:~* XIENCE V® and/or XIENCE nano™ and/or XIENCE PRIME™ LL Everolimus Eluting Coronary Stent~* HT PROGRESS and/or HT PILOT guide wires in recanalization~* MINI-TREK Coronary Dilatation Catheter in predilatation
Study: NCT01130779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib (TARCEVA®)
Description: Erlotinib 150mg/day, everyday
Study: NCT02639728

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular Coffee
Description: Regular coffee will be given a 4oz cup three times daily and will be instructed to consume all of its liquid contents.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Description: Decaffeinated coffee will be given a 4oz cup three times daily and will be instructed to consume all of its liquid contents.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm water
Description: Warm water will be given a 4oz cup three times daily and will be instructed to consume all of its liquid contents.
Study: NCT02624167

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NW-3509A
Description: Patients will be given oral doses of 15, 20 and 25 mg BID of NW-3509A
Study: NCT03346018

Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of aqueous humor and plasma samples
Description: The collected samples will be analyzed as follow:~1. Determination of the concentration of various cytokines, chemokines and groeth factors in aqueous humor and in the plasma.~2. Analysis of the mononuclear cells ( T helper lymphocytes CD3+ and CD4+, T cytotoxic lymphocytes CD3+ CD8+, B lymphocytes CD19+, Natural killer lymphocytes CD56+ and CD3- and monocytes CD14+) present in the aqueous humor by cytofluorimetry.~3. Evaluation of the presence of anti-human HSP70 antibodies in plasma samples by Western blot immunoprecipitation assays.~4. Whenever possible (adequate number of cells), in vitro stimulation of mononuclear cells presence in aqueous humor with epitopes from tuberculosis mycobacterium antigens and the analysis of cytokines production in the supernatants.
Study: NCT00727038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab (Lucentis)
Description: 0.5 mg ranibizumab intravitreal injection single dose administration
Study: NCT02624167

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be given oral dose of matching Placebo
Study: NCT00913796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium citrate
Description: 2.41 gram of citrate b.i.d. for 12 months. Dosage to be adjusted according to serum potassium concentration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium chloride
Description: 370 mg potassium t.i.d. for 12 months. Dosage to be adjusted according to serum postassium concentration.
Study: NCT03242616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed + Vinorelbine
Description: Vinorelbine (25 mg/m2, day 1 \& 8)~* Pemetrexed (500 mg/m2, day 1)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Vinorelbine (25 mg/m2, day 1 \& 8)
Study: NCT03699241

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: BG505 SOSIP.664 gp140, adjuvanted
Description: Dosage of 30ug, Intramuscular administration

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: BG505 SOSIP.664 gp140, adjuvanted
Description: Dosage of 30ug, Intramuscular administration

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: BG505 SOSIP.664 gp140, adjuvanted
Description: Dosage of 100ug, Intramuscular administration

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: BG505 SOSIP.664 gp140, adjuvanted
Description: Dosage of 100ug, Intramuscular administration

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: BG505 SOSIP.664 gp140, adjuvanted
Description: Dosage of 300ug, Intramuscular administration

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tris-NaCl Diluent

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tris-NaCl Diluent

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tris-NaCl Diluent

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tris-NaCl Diluent

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tris-NaCl Diluent
Study: NCT00873119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belinostat, carboplatin, paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin, paclitaxel
Study: NCT03727737

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial magnetic Stimulation
Description: RTMS will be delivered via magventure machine, on an approved FDA IDE protocol to DLPFC region to improve memory in older adults (veterans and non-veterans) with mild and moderate TBI.
Study: NCT04340999

Intervention type: DIAGNOSTIC_TEST
Intervention: Nerve conduction studies and Quantitative EMG ( MUNE and IPA)
Description: Nerve Conduction Studies: Electrophysiological method that tests the presence/absence of peripheral neuropathy.~MUNE: Electrophysiological technique that assess number of motor units. IPA: Electrophysiological method that assess interference pattern and hence, borderline cases of neuropathy/ myopathy
Study: NCT04392102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZL-2306(Niraparib）
Description: The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
Study: NCT04801719

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Habib™ EndoHPB; Boston Scientific, US; former EMcision Ltd., UK
Description: Randomised patients in selected arm received endoluminal RFA by 8F catheter (Habib™ EndoHPB; Boston Scientific, US; former EMcision Ltd., UK) before stenting procedure. Repeated ablations were processed through stenotic areas of bile ducts (10W, 90-120s, Rita 1500, Angiodynamics Ltd), all drained biliary tracts were used for introducing catheter and performance of ablation. Ablation procedure was followed with uncovered self-expandable metal stent insertion.
Study: NCT01758419

Intervention type: RADIATION
Intervention: Thallium-201 Myocardial Perfusion Study
Description: One-day Tl-201 stress/rest MPI protocol with pharmacological stress, as daily practice will be applied. CZT camera with multipinhole collimator and stationary detectors scan heart simultaneously. A 10% symmetrical energy window at 140 keV was used. Electrocardiogram-gated scans will be applied. Perfusion images were reconstructed in standard axis and polar maps of the left ventricle were obtained. Scans from CZT was analyzed in consensus by two experienced readers blinded to any information on patient identification. The software package Myovation for Alcyone, QGS and QPS were used for quantitative analysis of MPI polar maps. Automated analysis to determine ejection fraction.
Study: NCT05187858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNP3794
Description: LNP3794 capsules administered orally once daily
Study: NCT00502307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib (AV-951)
Description: solid oral dosage form taken daily for three weeks per one month cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: solid oral capsule containing excipients dosed daily for three weeks per month
Study: NCT01022684

Intervention type: OTHER
Intervention: Cross section study
Description: This is not intervention study. The purpose of the study is to examine the relationship between various inflammatory markers and PET imaging at the cross section setting
Study: NCT04221126

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMFI
Description: Tixel rapidly transfer thermal energy by a metallic pyramid tip that enable skin contact through integrated pulsed movements. The rapid heating dehydrates he epidermis and superficial dermis and creates micropores with no coagulative damage of surronding tissue.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMFI
Description: Tixel rapidly transfer thermal energy by a metallic pyramid tip that enable skin contact through integrated pulsed movements. The rapid heating dehydrates he epidermis and superficial dermis and creates micropores with no coagulative damage of surronding tissue.
Study: NCT03445130

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lavandula Angustifolia oil (LO)
Description: two drops on the inside of an oxygen face mask for 15 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Michelia Alba Leaf oil (MA)
Description: two drops on the inside of an oxygen face mask for 15 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Almond oil (AO)
Description: two drops on the inside of an oxygen face mask for 15 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: two drops on the inside of an oxygen face mask for 15 minutes.
Study: NCT03412318

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Twisted file
Description: Use of twisted file during cleaning and shaping of root canals

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mpro
Description: Use of Mpro during cleaning and shaping of root canals
Study: NCT01027299

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biventricular pacing
Description: Optimised temporary biventricular pacing.
Study: NCT02537314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: benzocaine
Description: 0.5% benzocaine solution in saline/hydrochloric acid administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo (saline) solution administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
Study: NCT03105700

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Repetitive transcranial magnetic stimulation (TMS) is a focal, nonpharmacological, noninvasive method for stimulating the brain and modulating neural network activity. To administer TMS, an electromagnetic coil is placed on the scalp, and uses electrical current to create magnetic fields that depolarize or hyperpolarize neurons in the brain.